| 引用本文: | 傅奕,李鑫,魏林,吴兆东,陈帮明,付义,刘永芳.Meta分析结合网络药理学的肾复康胶囊治疗慢性肾小球肾炎的疗效评价及其潜在作用机制研究[J].中国现代应用药学,2022,39(18):2367-2376. |
| FU Yi,LI Xin,WEI Lin,WU Zhaodong,CHEN Bangming,FU Yi,LIU Yongfang.Study on Efficacy Evaluation and Potential Mechanism of Shenfukang Capsule in Treatment to Chronic Glomerulonephritis by Meta Analysis and Network Pharmacology[J].Chin J Mod Appl Pharm(中国现代应用药学),2022,39(18):2367-2376. |
|
| |
|
|
| 本文已被：浏览 1136次 下载 891次 |
码上扫一扫！ |
|
|
| Meta分析结合网络药理学的肾复康胶囊治疗慢性肾小球肾炎的疗效评价及其潜在作用机制研究 |
|
傅奕1, 李鑫2, 魏林1, 吴兆东1, 陈帮明1, 付义1, 刘永芳1
|
|
1.江西省中医肾病临床医学研究中心, 九江市中医院, 江西 九江 332000;2.湖南中医药大学, 中医诊断学湖南省重点实验室, 中医心肺病证辨证与药膳食疗湖南省重点研究室, 长沙 410208
|
|
| 摘要: |
| 目的 结合meta分析与网络药理学研究策略，评价肾复康胶囊(Shenfukang capsule，SKC)治疗慢性肾小球肾炎(chronic glomerulonephritis，CGN)的临床疗效，并初步探索其作用机制。方法 全面检索SKC治疗CGN随机对照试验(randomized controlled trials，RCTs)研究的中英文文献，基于纳、排标准，确定定量文献，采用Review Manager对纳入数据meta分析。基于网络药理学方法，筛选SKC的化学成分及其作用靶点、疾病靶点、共有靶点等相关信息，随后基于生物信息学技术，进行关键通路的相关注释，探讨SKC干预CGN潜在机制。结果 共纳入11项RCTs，合计938例受试者。Meta分析显示，在有效率、淋巴细胞亚群(CD4、CD4/CD8升高，CD8下降)、纤溶系统以及肾功能指标方面，治疗组均优于对照组(P<0.05)。通过在线数据库共得到27个化学成分和97个潜在靶标干预的CGN关系极为密切，主要涉及AGE/RAGE通路、脂质和动脉粥样硬化、TNF信号通路、IL-17信号通路等多条信号通路等分子过程。结论 SKC干预CGN是多成分、多靶点、多环节的整合效应，其机制可能通过调控自身免疫、氧化应激、炎症反应等途径而达到治疗目的。 |
| 关键词: 肾复康胶囊 慢性肾小球肾炎 meta分析 网络药理学 临床评价 潜在机制 |
| DOI：10.13748/j.cnki.issn1007-7693.2022.18.011 |
| 分类号:R966 |
| 基金项目:国家自然科学基金项目(82060839);江西省卫生健康委科技计划(20204305);江西省中医药科研计划(2019A395) |
|
| Study on Efficacy Evaluation and Potential Mechanism of Shenfukang Capsule in Treatment to Chronic Glomerulonephritis by Meta Analysis and Network Pharmacology |
|
FU Yi1, LI Xin2, WEI Lin1, WU Zhaodong1, CHEN Bangming1, FU Yi1, LIU Yongfang1
|
|
1.Jiangxi Provincial Clinical Medicine Research Center of Chinese Medicine Nephropathy, Jiujiang Hospital of Chinese Medicine, Jiujiang 332000, China;2.Hunan University of Chinese Medicine, Hunan Provincial Key Laboratory of Diagnostics of Chinese Medicine, Hunan Provincial Key Laboratory of Syndrome Differentiation of Cardio-pulmonary Disease and Chinese Medicative Diet for Food Therapy, Changsha 410208, China
|
| Abstract: |
| OBJECTIVE To investigate clinical efficacy evaluation and potential mechanism of Shenfukang capsule (SKC) in treatment to chronic glomerulonephritis (CGN) based on integration meta analysis and network pharmacology research strategy. METHODS The Chinese and English literature of the randomized controlled trials (RCTs) about SKC in treatment on CGN were comprehensively searched.The quantitative literature was determined based on the criteria of inclusion and exclusion.The meta analysis of the included data was carried out by the Review Manager.The chemical components and the target of action,disease targets,common targets,and other related information of SKC were screened based on network pharmacology.The key pathway was annotated,and the potential mechanism of SKC intervention in CGN was explored based on bioinformatics technology.RESULTS A total of 11 RCTs were included,which were involving 938 patients.Meta analysis showed that the effective rate,lymphocyte subsets (CD4,CD4/CD8 increased and CD8 decreased),fibrinolytic system,and renal function indexes in the therapy group were superior to those in the control group (P<0.05).A total of 27 chemical components and 97 potential targets extremely closely related to CGN were obtained through the online database,which was related to AGE/RAGE pathway,lipid and atherosclerosis,TNF signaling pathway,IL-17 signaling pathway,and other molecular processes.CONCLUSION SKC intervention in CGN is an integration effect of multi-component,multi-target,multi-links integration effect,mainly through the regulation of autoimmunity,oxidative stress,inflammatory response,and other ways to achieve therapeutic purposes. |
| Key words: Shenfukang capsule chronic glomerulonephritis meta analysis network pharmacology clinical evaluation potential mechanism |
|
|
|
|
